截至今日:Aug 14, 12:54:35 GMT-4
No Data Yet
Kirby McInerney LLP opened a securities investigation into Dr. Reddy's Laboratories after its shares fell 9 percent on a ₹2.4 billion semaglutide provision and Q1 FY2027 earnings miss.
Dr. Reddy's Laboratories shares fell about 9 percent after a Q1 FY27 earnings miss and a ₹2.4 billion provision tied to out-of-spec semaglutide batches, prompting a securities investigation.
Dr. Reddy's Laboratories shares fell 9% after reporting Q1 FY27 results with a 68.7% profit decline and 5.66% revenue drop, triggering an investor investigation.
Dr Reddy's CEO warns that Trump's 100% tariff on generic drug imports will raise medicine costs for US patients, threatening India's $9.7 billion pharma export market.
Dr. Reddy's Laboratories Ltd 的当前价格为 $12.25,在上个交易日 下降 了 1.32%。
Dr Reddy's Laboratories Ltd 属于 Pharmaceuticals 行业,该板块是 Health Care
Dr Reddy's Laboratories Ltd 的当前市值是 $10.2B
据华尔街分析师称,共有 39 位分析师对 Dr Reddy's Laboratories Ltd 进行了分析师评级,包括 8 位强烈买入,11 位买入,12 位持有,8 位卖出,以及 8 位强烈卖出